Loading clinical trials...

Ezetimibe for Patients With Chronic Hepatitis D | Clinical Trials | Clareo Health

UNKNOWNPHASE2

Ezetimibe for Patients With Chronic Hepatitis D

NCT03099278•Ziauddin Hospital

Summary

Ezetimibe possesses pharmacophore features to inhibit NTCP, the receptor required for HBV and HDV hepatocyte entry that include two hydrophobes and one hydrogen bond acceptor. Therapy with Ezetimibe may lead to decline in hepatitis D virus levels. The aim of the study is to evaluate the utility of Ezetimibe in patients with chronic HDV infection

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Treatment experienced patients; non-responders of relapsers of pegylated interferon therapy
•Age 18 years or above
•Presence of anti-HDV in serum
•Presence of quantifiable HDV RNA in serum
•Elevated ALT \> ULN

Exclusion Criteria

•Decompensated liver disease
•Patients with ALT levels greater than 10 times ULN (400 U/L)
•Pregnancy or inability to practice adequate contraception.
•Significant systemic or major illnesses other than liver disease, including, but not limited to, congestive heart failure, renal failure (eGFR\<50 ml/min), organ transplantation, serious psychiatric disease or depression and active coronary artery disease.
•Systemic immunosuppressive therapy
•Evidence of another form of liver disease in addition to viral hepatitis
•Active substance abuse, such as alcohol or injection drugs
•Hepatocellular carcinoma
•Concurrent hepatitis C infection or HIV coinfection
•Diagnosis of malignancy in the five years
+4 more criteria

Locations (1)

Ziauddin University Hospital

Karachi, Sindh, Pakistan

Key Dates

Start Date

January 1, 2017

Primary Completion Date

June 1, 2017

Completion Date

October 1, 2017

Last Updated

April 4, 2017

Enrollment

ESTIMATED participants

Conditions

Chronic Hepatitis D

Interventions

Ezetimibe

DRUG

Contacts

Zaigham Abbas

CONTACT

922135862937 drzabbas@gmail.com

Study of Bulevirtide in Participants With Chronic Hepatitis D Infection

NCT05718700

Chronic Hepatitis D Infection

View study

COMPLETED

Burden of Hepatitis D Virus (HDV) Infection in Italy

NCT05723068

Chronic Hepatitis D

View study

WITHDRAWNPHASE2

Peginterferon Lambda and Lonafarnib Boosted With Ritonavir 48-Week Combination Therapy for Delta Hepatitis

NCT05953545

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 4, 2017Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions